Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease

Annals of Surgical Oncology

Volumn 17, Issue 6, 2010, Pages 1642-1648

  Wimberger, Pauline ^a   Wehling, Michael ^a   Lehmann, Nils ^a   Kimmig, Rainer ^a   Schmalfeldt, Barbara ^b   Burges, Alexander ^c   Harter, Philipp ^d   Pfisterer, Jacobus ^e   Du Bois, Andreas ^d  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

^e Academic Hospital Solingen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MULTICENTER STUDY; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77954817628     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0964-9     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106-130
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-592
3. Du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16(Suppl 8):viii7-12.
4. International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987;156:263-264
5. Curtin JP, Malik R, Venkatraman ES, et al. Stage IV ovarian cancer: impact of sugical debulking. Gynecol Oncol. 1997;64:9-12.
6. Akahira JI, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:298-403.
7. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278-287
8. Repetto L, Chiara S, Pace M, et al. Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens. Tumori. 1990;76:274-277
9. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161-92.
10. Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2007;25:3621-3627
11. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259
12. Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390-396
13. Goff BA, Matthews BJ, Larson EH, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer. 2007;109:2031-2042
14. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98:172-180
15. Winter WE III, Maxell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:83-89
16. Goodman HM, Harlow BL, Sheets EE, et al. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol. 1992;46:367-371
17. Liu PC, Benjamin I, Morgan MA, et al. Effect of surgical debulking on survival in stage IV ovarain cancer. Gynecol Oncol. 1997;64:4-8.
18. Munkarah AR, Hallum AV, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997;64:13-17
19. Du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel a first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-1329
20. Du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 2006;24:1127-1135
21. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III rial to topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98:1036-1045
22. Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 mulitcenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe dI'nvestigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-1244
23. Benedet JL, Bender H, Jones H III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209-262
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481
25. Cox DR, Oakes D. Analysis of Survival Data. London, UK: Chapman and Hall; 1984.
26. Crawford SC, Vasex PA, Paul J, et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trail. J Clin Oncol. 2005;23:8802-8811
27. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007;104:480-490
28. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovaran cancer? Metaanalysis of 21 studies. Ann Surg Oncol. 2009:16:2315-2320
29. Vergote CG, Trope F, Amant GB, et al. EORTC-GCG/NCICCTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (abstract). Plenary presentation at the 12th Biennal meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand, October 25-28, 2008.
30. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044 (Pubitemid 41095036)